Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma
- 21 October 2004
- journal article
- Published by Springer Nature in Leukemia
- Vol. 19 (1) , 154-156
- https://doi.org/10.1038/sj.leu.2403541
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myelomaBritish Journal of Haematology, 2004
- Clinical activity of arsenic trioxide for the treatment of multiple myelomaLeukemia, 2002
- Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: A single center experienceAmerican Journal of Hematology, 2002
- United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic LeukemiaJournal of Clinical Oncology, 2001
- Studies on Treatment of Acute Promyelocytic Leukemia With Arsenic Trioxide: Remission Induction, Follow-Up, and Molecular Monitoring in 11 Newly Diagnosed and 47 Relapsed Acute Promyelocytic Leukemia PatientsBlood, 1999